HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma

Virchows Archiv

Volumn 461, Issue 5, 2012, Pages 521-530

  Lee, Hee Jin ^a   Chung, Joon Yong ^b   Hewitt, Stephen M ^b   Yu, Eunsil ^a   Hong, Seung Mo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bile duct; Cholangiocarcinoma; Extrahepatic; HER2; HER3; Immunohistochemistry; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOPLASM; DISEASE ASSOCIATION; EXTRAHEPATIC CHOLANGIOCARCINOMA; FEMALE; GENE OVEREXPRESSION; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE CARCINOMA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PAPILLOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ADENOCARCINOMA; BILE DUCT NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, PAPILLARY; CELL MEMBRANE; CHOLANGIOCARCINOMA; CYTOPLASM; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84871615188     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1321-0     Document Type: Article

References (62)

1. Malhi H, Gores GJ (2006) Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45:856-867 (Pubitemid 44646688)
2. Hong SM, Kim MJ, Pi DY, Jo D, Cho HJ, Yu E, Ro JY (2005) Analysis of extrahepatic bile duct carcinomas according to the New American Joint Committee on Cancer staging system focused on tumor classification problems in 222 patients. Cancer 104:802-810 (Pubitemid 41113681)
3. Nagakawa T, Kayahara M, Ikeda S, Futakawa S,KakitaA,Kawarada H, Matsuno M, Takada T, Takasaki K, Tanimura H, Tashiro S, Yamaoka Y (2002) Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg 9:569-575 (Pubitemid 36305102)
4. Seyama Y, Makuuchi M (2007) Current surgical treatment for bile duct cancer. World J Gastroenterol 13:1505-1515 (Pubitemid 46672657)
5. Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD (2007) Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11:1488-1496, discussion 1496-1487
6. Thomas MB (2007) Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 61:44-51 (Pubitemid 44880150)
7. Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15:413-448 (Pubitemid 351822188)
8. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91:8132-8136
9. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516 (Pubitemid 44036456)
10. Hsieh AC, Moasser MM (2007) Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 97:453-457 (Pubitemid 47258458)
11. Poller DN, Spendlove I, Baker C, Church R, Ellis IO, Plowman GD, Mayer RJ (1992) Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. J Pathol 168:275-280
12. Sanidas EE, Filipe MI, Linehan J, Lemoine NR, Gullick WJ, Rajkumar T, Levison DA (1993) Expression of the c-erbB-3 gene product in gastric cancer. Int J Cancer 54:935-940 (Pubitemid 23267465)
13. Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, Wojnar A (1998) Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 18:2727-2732 (Pubitemid 28386573)
14. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ, Salomon DS (1991) Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A 88:7792-7796 (Pubitemid 21915240)
15. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M, Buchler MW (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29:771-777 (Pubitemid 28375981)
16. Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, TavassoliM, Spaventi S, Pavelic K, Spaventi R (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126:205-211 (Pubitemid 30183023)
17. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46. doi:1471-2407-6-46
18. Friess H, Wang L, Zhu Z, Gerber R, Schroder M, Fukuda A, Zimmermann A, Korc M, Buchler MW (1999) Growth factor receptors are differentially expressed in cancers of the papilla of Vater and pancreas. Ann Surg 230:767-774, discussion 774-765
19. Friess H, Yamanaka Y, Kobrin MS, Do DA, Buchler MW, Korc M (1995) Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1:1413-1420
20. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 98:418-425 (Pubitemid 351161240)
21. Su WC, Shiesh SC, Liu HS, Chen CY, Chow NH, Lin XZ (2001) Expression of oncogene products HER2/Neu and Ras and fibrosisrelated growth factors bFGF, TGF-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 46:1387-1392
22. Harder J, Waiz O, Otto F, Geissler M, Olschewski M, Weinhold B, Blum HE, Schmitt-Graeff A, Opitz OG (2009) EGFR and HER2 expression in advanced biliary tract cancer. World J Gastroenterol 15:4511-4517
23. Shafizadeh N, Grenert JP, Sahai V, Kakar S (2010) Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder. Hum Pathol 41:485-492
24. Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM (2009) The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 15:660-667
25. Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SM, Moskaluk CA, Hewitt SM (2011) Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med 9:126. doi:1479-5876-9-126
26. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805 (Pubitemid 351724903)
27. Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14:3550-3558 (Pubitemid 24160762)
28. Prigent SA, Gullick WJ (1994) Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13:2831-2841
29. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021-5026
30. Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878-5887
31. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938 (Pubitemid 36899201)
32. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441 (Pubitemid 46160912)
33. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043 (Pubitemid 46799492)
34. Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A (2008) HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14:5188-5197
35. Lozano JJ, Soler M, Bermudo R, Abia D, Fernandez PL, Thomson TM, Ortiz AR (2005) Dual activation of pathways regulated by steroid receptors and peptide growth factors in primary prostate cancer revealed by factor analysis of microarray data. BMC Genomics 6:109. doi:1471-2164-6-109
36. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape KD, Wistuba II (2009) HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15:4829-4837
37. Simpson BJ, Weatherill J, Miller EP, Lessells AM, Langdon SP, Miller WR (1995) c-erbB-3 protein expression in ovarian tumours. Br J Cancer 71:758-762
38. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, Soares FA Jr (2011) Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 29:3030-3036
39. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, Cagle PT (1997) High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 10:142-148 (Pubitemid 27110039)
40. Kluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, Rimm DL (2004) Her2/neu is not a commonly expressed therapeutic target in melanoma - a large cohort tissue microarray study. Melanoma Res 14:207-210 (Pubitemid 38879583)
41. Ueno Y, Sakurai H, Tsunoda S, Choo MK, Matsuo M, Koizumi K, Saiki I (2008) Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 123:340-347 (Pubitemid 351842018)
42. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 102:3788-3793 (Pubitemid 40354690)
43. Soler M, Mancini F, Meca-Cortes O, Sanchez-Cid L, Rubio N, Lopez-Fernandez S, Lozano JJ, Blanco J, Fernandez PL, Thomson TM (2009) HER3 is required for the maintenance of neuregulindependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer 125:2565-2575
44. Jan YY, Yeh TS, Yeh JN, Yang HR, Chen MF (2004) Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma. Ann Surg 240:89-94
45. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206:356-365 (Pubitemid 40903200)
46. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C (2006) Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074 (Pubitemid 46638942)
47. Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A (2007) Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol 60:295-303 (Pubitemid 46742546)
48. Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, Bralet MP (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72:105-110 (Pubitemid 350249137)
49. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W (2008) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99:862-867
50. Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N, Kennedy T (2008) Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer. Am J Clin Oncol 31:140-144 (Pubitemid 351519165)
51. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Tsuneyoshi M (2002) c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 40:269-278 (Pubitemid 34227118)
52. Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, Grigioni WF (2003) Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis 35:332-338 (Pubitemid 41110860)
53. Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH, Su WC (1995) Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 15:1055-1059
54. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE (2002) ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36:439-450 (Pubitemid 34810365)
55. Terada T, Ashida K, Endo K, Horie S, Maeta H, Matsunaga Y, Takashima K, Ohta T, Kitamura Y (1998) c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 33:325-331 (Pubitemid 28508881)
56. Ukita Y, Kato M, Terada T (2002) Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol 36:780-785 (Pubitemid 35177407)
57. Voravud N, Foster CS, Gilbertson JA, Sikora K, Waxman J (1989) Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 20:1163-1168 (Pubitemid 20034145)
58. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti AI (2010) AJCC cancer staging manual. Springer, New York
59. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL (1996) Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224:463-473, discussion 473-465
60. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F,Winter JM, Lillemoe KD, Choti MA, Yeo CJ, Schulick RD (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245:755-762 (Pubitemid 46684105)
61. Argani P, Shaukat A, Kaushal M, Wilentz RE, Su GH, Sohn TA, Yeo CJ, Cameron JL, Kern SE, Hruban RH (2001) Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts. Cancer 91:1332-1341 (Pubitemid 32267045)
62. Watanabe A, Cornelison R, Hostetter G (2005) Tissue microarrays: applications in genomic research. Expert Rev Mol Diagn 5:171-181 (Pubitemid 40396223)